NCT06171282View on ClinicalTrials.gov

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 12, 2023

Primary Completion Date

July 12, 2025

Study Completion Date

July 12, 2026

Conditions
OsteosarcomaSarcomaSoft Tissue SarcomaBone Tumor
Interventions
DRUG

Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Trial Locations (1)

Unknown

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

lead

Shanghai Yunying Medical Technology

INDUSTRY